Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Protein-protein Interaction

Abstract LB-C02: In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex

SANG-KYU KIM, RICHARD C FOITZIK, SONGHUI LI, ANDREW VINSON, ALEX SHMAYLOV, KAREN JARVIS, SUSAN JAMES, SCOTT R WALKER, MARK YORK, BENJAMIN CAO, SUSAN K NILSSON and RICKY W JOHNSTONE
SANG-KYU KIM
1MecRx Pty Ltd, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICHARD C FOITZIK
1MecRx Pty Ltd, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SONGHUI LI
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREW VINSON
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALEX SHMAYLOV
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAREN JARVIS
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSAN JAMES
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SCOTT R WALKER
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARK YORK
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BENJAMIN CAO
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSAN K NILSSON
2CSIRO Manufacturing, Melbourne;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RICKY W JOHNSTONE
3The Peter MacCallum Cancer Centre, Melbourne.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-19-LB-C02 Published December 2019
  • Article
  • Info & Metrics
Loading
Abstracts: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; October 26-30, 2019; Boston, MA

Abstract

The expression and activity of the Myc oncoprotein is frequently dysregulated in human cancers due to Myc amplification, translocation, protein stabilization and/or convergence of oncogenic signaling pathways on Myc. Therapeutic inhibition of Myc is highly desirable however, prior efforts to identify specific and direct pharmacological inhibitors of Myc function have generally failed to yield Myc-selective drug-like small molecules. Herein, we have comprehensively profiled previously reported small molecule inhibitors of the Myc-Max heterodimeric complex (10058-F4, 10074-G5, MYCMI-6, KI-MS2-001/-008 (KI-MS2), Mycro3 & JKY-2-169), using an in vitro biological screening cascade in an effort to identify and characterize bona fide tool compounds for our Myc drug discovery program. Initial cellular screening of compounds using a reporter construct containing Myc binding elements upstream of the luciferase gene and cellular viability assays using the P493-6 (Myc On / Off) system identified JKY-2-169 (JKY) and KI-MS2 as compounds with on-target activity and acceptable specificity profiles to warrant further characterization. Consistent with its reported mode of action, we confirmed JKY perturbs binding of the c-Myc/MAX heterodimer to its canonical E-box DNA sequence without causing protein-protein dissociation through biochemical and in vitro Myc:MAX interaction assays. In a cellular thermal shift assay (CETSA) using P493-6 B-cells, JKY induced thermal stabilization of c-Myc and not MAX, suggesting direct and specific cellular engagement of JKY to Myc. Consistent with this, JKY phenocopied the genetic de-induction of c-Myc in P493-6 cells, inducing G0/G1 cell-cycle arrest in a dose-dependent manner. Moreover, 3’RNA-Sequencing (3’RNA-Seq.) of MV4-11 AML cells and P493-6 cells treated with JKY demonstrated an altered transcriptional program consistent with Myc deregulation that was independent of transcriptional modulation of Myc expression. Further transcriptional profiling revealed JKY exhibits a profile with high correlation to that of the small molecule MAX inhibitor, KI-MS2; consistent with the obligate dependence of Myc on heterodimerization with MAX for transcriptional activation. Together, these results highlight JKY and KI-MS2 as suitable chemical tools for deciphering Myc biology. MecRx’s small molecule Myc inhibitor MRX-1669 was developed using several orthogonal biochemical/biophysical assays including those described above. Similar to JKY, MRX-1669 exhibits cellular Myc engagement (CETSA), and evokes a similar transcriptional profile to that of JKY and KI-MS2 (3’RNA-Seq.). MRX-1669 is a drug-like molecule that provided a benchmark for further development and medicinal chemistry optimization.

Citation Format: SANG-KYU KIM, RICHARD C FOITZIK, SONGHUI LI, ANDREW VINSON, ALEX SHMAYLOV, KAREN JARVIS, SUSAN JAMES, SCOTT R WALKER, MARK YORK, BENJAMIN CAO, SUSAN K NILSSON, RICKY W JOHNSTONE. In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr LB-C02. doi:10.1158/1535-7163.TARG-19-LB-C02

  • ©2019 American Association for Cancer Research.
Previous
Back to top
Molecular Cancer Therapeutics: 18 (12 Supplement)
December 2019
Volume 18, Issue 12 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-C02: In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract LB-C02: In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex
SANG-KYU KIM, RICHARD C FOITZIK, SONGHUI LI, ANDREW VINSON, ALEX SHMAYLOV, KAREN JARVIS, SUSAN JAMES, SCOTT R WALKER, MARK YORK, BENJAMIN CAO, SUSAN K NILSSON and RICKY W JOHNSTONE
Mol Cancer Ther December 1 2019 (18) (12 Supplement) LB-C02; DOI: 10.1158/1535-7163.TARG-19-LB-C02

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-C02: In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex
SANG-KYU KIM, RICHARD C FOITZIK, SONGHUI LI, ANDREW VINSON, ALEX SHMAYLOV, KAREN JARVIS, SUSAN JAMES, SCOTT R WALKER, MARK YORK, BENJAMIN CAO, SUSAN K NILSSON and RICKY W JOHNSTONE
Mol Cancer Ther December 1 2019 (18) (12 Supplement) LB-C02; DOI: 10.1158/1535-7163.TARG-19-LB-C02
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Protein-protein Interaction

  • Abstract LB-B17: Characterization of small molecule inhibitors of the Nrf2-Keap1 interaction using MicroScale Thermophoresis
  • Abstract B155: The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα
Show more Protein-protein Interaction

Protein-protein Interaction: Poster Presentations - Proffered Abstracts

  • Abstract LB-B17: Characterization of small molecule inhibitors of the Nrf2-Keap1 interaction using MicroScale Thermophoresis
  • Abstract B155: The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα
  • Abstract LB-C02: In vitro on-target and selectivity profiling of small-molecule inhibitors of the Myc/Max heterodimeric complex
Show more Protein-protein Interaction: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement